期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

伊立替康治疗宫颈癌的临床研究进展 被引量：3

暂未订购
导出
摘要 伊立替康（irinotecan,CPT-11）是喜树碱类衍生物,属拓扑异构酶I（Topo I）抑制剂,最早由日本研制开发,1987年开始I期临床实验,1998年获得美国FDA批准,用于标准化疗方案治疗失败后转移性结直肠癌的一线治疗.
作者 王苗苗 张国楠
机构地区 成都中医药大学 四川省肿瘤医院
出处 《肿瘤预防与治疗》 2010年第2期167-171,共5页 Journal of Cancer Control And Treatment
关键词 伊立替康 宫颈癌 化疗
分类号 R737.33 [医药卫生—肿瘤] R730.53 [医药卫生—肿瘤]
  • 相关文献

参考文献25

  • 1Wall ME,Wani MC,Cook CE,et al Plant antitumor agents:the isolation and structure of camptothecine,a novel alkaloidal leukemia and tumor inhibitor from Camptotheca acuminata[J].Am Chem Soc,1966,88:3888-3890.
  • 2Ron M,Robbert A,Jaap V,et al.Clinical pharmacokinetics and metabolism of irinotecan(CPT-11)[J].Clin Cancer Res,2001,7:2182-2194.
  • 3Rujia Xie,Ron Mathijssen,Alex Sparreboom,et al Clinical pharmacokineties of irinotecan and its metabolites:A population analysis[J].J Clin Oncol,2002,20(15):3293-3301.
  • 4Combes O,Barre J,Duche JC,et al.In vitro binding and partitioning of irinotecan(CPT-11)and its metabolite,SN-38,in human blood[J].Invest New Drugs,2000,18(1):1-5.
  • 5Pitot HC,Goldberg RM,Reid JM,et al Phase Ⅰ dose-finding and pharmaco-kinetic aial of irinoteean hydrochloride(CPT-11)using a once-every-three-week dosing schedule for patients with advanced solid tumor malignancy[J].Clin Cancer Res,2000,6(6):2236-2244.
  • 6Maja JA de Jonge,Alex S,André ST Planting,et al.Phase Ⅰ study of 3-week schedule of irinotecan combined with cisplatin in patients with advanced solid tumors[J].J Clin Oncol,2000,18(1):187.
  • 7Machida S,Ohwada M,Fujiwara H,et al.Phase Ⅰ study of combination chemotherapy using irinotecan hydreehloride and nedaplatin for advanced or recurrent cervical cancer[J].Oncology,2003,65:102-107.
  • 8Verschraegen CF.Irinoteean for the treatment of cervical cancer[J].Oncology(Williston Park),2002,16(5):32-34.
  • 9Sugiyama T,Yakushiji M,Noda K,et al.Phase Ⅱ study of irinotocan and cisplatin as first-line chemotherapy in advanced or recurrent cervical cancer[J].Oncology,2000,58(1):31-37.
  • 10Chitapanarax I,Tonusin A,Sukthomya V,et al.Phase Ⅱ clinical study of irinotecan and cisplatin as first-line chemotherapy in metastatic or recurrent cervical cancer[J].Gynecol Oncol,2003,89(3):402-407.

二级参考文献11

  • 1Lahousen M, Pickel H, Tamussino K. Chemotherapy for advanced and/or recurrent cervical cancer. Arch Gynecol, 1987,240,247-252.
  • 2Omura GA. Current status of chemotherapy for cancer of the cervix.Oncology, 1992,6,27-32.
  • 3Thigpen T, Vance R, Puneky L, et al. Chemotherapy as a palliative treatment in carcinoma of the uterine cervix. Semin Oncol, 1995,22,16-24.
  • 4Hertzberg RP, Caranfa MH, Hecht SM. On the mechanism of topoisomerase Ⅰ inhibition by campothecin:Evidence for binding to an enzyme DNA complex. Biochemistry, 1989, 28,4629-4638.
  • 5Catherine Lhomme, Pierre Fumoleau, Pierre Fargeot, et al. Results of European Organization for research and treatment of cancer/early clinical studies group phase Ⅱ trial of first line irinotecan in patients with advanced or recurrent squamous cell carcinoma of the cervix. J Clinical Oncology, 1999,17,3136-3142.
  • 6Sugiyama T, Nishida T, Kumagai S, et al. Combination therapy with irinotecan and cisplafin as neoadjuvant chemotherapy in locally advanced cervical cancer. Br J Cancer, 1999,81,95-98.
  • 7Chitapmmmx I, onusin A, Sukthomya V, et aL Phase Ⅱ clinical study of ifinotecan and cisplatin as first line chemotherapy in metastatic or recurrent cervical cancer. Gynecol Oncol, 2003,89,402-407.
  • 8Machida S, Ohwada M, Fujiwara H, et al. Phase I combination chemotherapy using irinotecan hydrochlofide and nedaplatin for advanced or recurrent cervical cancer. Oncology,2003,65,102-107.
  • 9Sugiyama T, Yakushiji M, Noda K, et al. Phase Ⅱ study ofifinotecan and cisplatin as first line chemotherapy in advanced or recurrent cervical cancer. Oncology, 2000, 58, 31-37.
  • 10Mathijssen RHJ, Verweij J, Loos WJ, et aL Irinotecan pharmacokinetics-pharmacodynamics: the clinical relevance of prolonged exposure to SN-38. British J Cancer, 2002,87,144-150.

共引文献23

同被引文献22

  • 1Siegel R, Ward E, Brawley O, et al. Cancer statistics, 2011 : the impact of eliminating socioeconomic and racial dispari- ties on premature cancer deaths [ J ]. CA Cancer J Clin, 2011,61 (42) :212.
  • 2Looi M D, Hatta M A, Siti Aishah, et al. Serum levels of squamous cell carcinoma antigen and CA 125 in cervical intraepithelial neoplasia and invasive squamous cell carci- noma of the uterine cervix [ J ]. International Journal of Cancer Research,2011,2 ( 3 ) :26.
  • 3Park Sung Taek, Song Min Jong, Park Jong Sup. Incidence and clinicopathologic behavior of uterine cervical carcinoma in renal transplant recipients [ J ]. World Journal of Surgical Oncology,2011,9( 1 ) : 129.
  • 4Selvakumari E, Shantha S, Purushoth Prabhu T. Antiprolif- erative activity of ethanolic flower extract from nymphaea pubescens willd against human cervical and breast carcino- ma in vitro [ J ]. International Research Journal of Pharma- cy,2012,3(1) :1101.
  • 5Linde A, Streefkerk M, Schuurman H J. Divergence between the occurrence of antibody and cellular immune reactivity to cervical carcinoma cell lines in preinvasive and macroinva- sire stages of cervical carcinoma[ J]. International Research Journal of Pharmacy,2009,32(2) :16.
  • 6Matsumura M,Takeshima N,Ota T,et al.Neoadjuvant chemotherapy followed by radical hysterectomy plus postoperative chemotherapy but no radiotherapy for Stage IB2-IIB cervical cancer-irinotecan and platinum chemotherapy[J].Gynecol Oncol,2010,119(2):212-216.
  • 7宋颖秋,伍钢,李贵玲,陈静,曹如波,尹中元,朱芳.盐酸伊立替康对局部晚期宫颈癌放射增敏的临床研究[J].临床肿瘤学杂志,2008,13(8):730-733. 被引量：5
  • 8毛晓敏,赵家菊,史元梅.盐酸伊立替康联合顺铂方案治疗宫颈癌21例毒副反应观察及护理[J].中国误诊学杂志,2008,8(32):7951-7952. 被引量：3
  • 9孙晓东,岳树香,李建伟.盐酸伊立替康临床应用研究进展[J].中国药业,2011,20(14):79-80. 被引量：14
  • 10陈克明,易村犍,易清华,魏华.宫颈癌术前使用伊立替康联合顺铂方案化疗的近期疗效观察[J].中华妇幼临床医学杂志（电子版）,2011,7(4):290-291. 被引量：9

引证文献3

二级引证文献26

肿瘤预防与治疗
2010年 第2期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部